Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra director Thomas Wilder reported an equity award and updated holdings. He acquired 589 shares of common stock via restricted stock units granted at no cost, which vest in four equal installments on March 31, June 30, September 30, and December 31, 2026. The filing also notes 4,506 shares held indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
Penumbra Inc executive Johanna Roberts, EVP, General Counsel & Secretary, reported equity compensation activity in the form of restricted stock units (RSUs) and related tax withholding. On February 13, 2026, she was granted 2,630 RSUs that vest in four equal installments on February 15 of 2026, 2027, 2028 and 2029, subject to continued service. On February 17, 2026, she received another 2,630 RSUs, vesting annually in four equal installments beginning February 15, 2027, also subject to continued service. The footnotes state that if the Closing of the merger agreement among Penumbra, Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs from these grants will fully vest at that Closing, provided she remains in service through that date. In connection with RSU vesting, 482 shares of common stock were disposed of at $339.30 per share to cover tax withholding obligations, a non-open-market, tax-withholding disposition. Following these transactions, she directly owned tens of thousands of Penumbra common shares, with portions subject to vesting.
Penumbra Inc Chief Financial Officer Maggie Yuen reported multiple equity-related transactions in company common stock. On February 13, 2026, she was granted 2,630 restricted stock units (RSUs) under Penumbra’s Amended and Restated 2014 Equity Incentive Plan, scheduled to vest in four equal annual installments starting February 15, 2026, subject to continued service. On February 17, 2026, she received an additional 2,630 RSUs, vesting annually beginning February 15, 2027, also subject to continued service. Any unvested RSUs from these grants will fully vest if the Closing of the merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., as defined in the January 14, 2026 merger agreement, occurs while she remains in service. In connection with RSU vesting, 481 shares of common stock were withheld by Penumbra on February 15, 2026 at $339.30 per share to satisfy tax withholding obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, Yuen directly owned 20,785 shares of Penumbra common stock.
Penumbra Inc Chief Accounting Officer Lambert Shiu reported multiple equity compensation transactions involving company common stock. On February 13, 2026, he was granted 2,300 restricted stock units (RSUs) at $0 under Penumbra's Amended and Restated 2014 Equity Incentive Plan, with one quarter scheduled to vest on each of February 15, 2026, 2027, 2028 and 2029, subject to continued service. On February 17, 2026, he received an additional 2,300 RSUs at $0, vesting in four equal annual installments beginning February 15, 2027, also subject to continued service.
The filing notes that if the Closing defined in the January 14, 2026 merger agreement with Boston Scientific Corporation occurs, any unvested RSUs from these grants will fully vest at that Closing, provided he remains in service through that date. On February 15, 2026, 412 shares of common stock were disposed of at $339.30 per share to satisfy tax withholding obligations related to RSU vesting, rather than an open-market sale. After these transactions, he directly owned 39,473 shares of Penumbra common stock, a portion of which remains subject to vesting, and an additional 300 shares are held indirectly through his spouse's IRA.
Penumbra Inc President Shruthi Narayan reported equity compensation and related tax share withholding. On February 13, 2026, she received a grant of 2,630 restricted stock units (RSUs) that vest in four equal annual installments on February 15, 2026, 2027, 2028 and 2029, subject to continued service. On February 15, 2026, 705 common shares were withheld at $339.30 per share to satisfy tax obligations upon RSU vesting, a non‑market disposition. On February 17, 2026, she received an additional 2,630 RSUs vesting in four equal annual installments beginning February 15, 2027. The RSU footnotes state that if the Closing defined in the January 14, 2026 merger agreement with Boston Scientific Corporation occurs, any unvested RSUs will fully vest at that Closing, subject to continued service through that date.
FMR LLC and Abigail P. Johnson report a 4.7% beneficial stake in Penumbra Inc. common stock. As of the January 30, 2026 event date, they report beneficial ownership of 1,826,862.09 shares, with FMR holding sole voting power over 1,822,618 shares and sole dispositive power over 1,826,862.09 shares.
The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Penumbra. It also notes that one or more other persons may receive dividends or sale proceeds, but no such person holds more than 5% of the class.
FMR LLC has filed Amendment No. 10 to its Schedule 13G reporting a significant ownership stake in Penumbra Inc. As of December 31, 2025, FMR LLC and related entities beneficially owned 5,100,142.02 shares of Penumbra common stock, representing 13.0% of the outstanding class.
FMR LLC reported sole voting power over 5,086,654 shares and sole dispositive power over 5,100,142.02 shares. Abigail P. Johnson is also a reporting person, with sole dispositive power over the same 5,100,142.02 shares and no voting power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Penumbra.
Boston Scientific used its Q4 2025 call to highlight strong growth and the pending acquisition of Penumbra. The Cardiovascular segment grew 16% operationally and organically in the quarter and 21% organic for the full year, reflecting strength in fast-growing markets.
As of December 31, 2025, the company reported cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9x. All three major rating agencies affirmed its single A minus equivalent credit rating, and Fitch raised its outlook from stable to positive.
Management closed the acquisition of Nalu Medical and announced deals for Valencia Technologies and Penumbra, expanding into urology and neurovascular/mechanical thrombectomy adjacencies. The CEO reaffirmed long-range goals for 10%+ organic revenue growth from 2026–2028, about 150 bps margin expansion, and strong double-digit EPS growth, while cautioning that these are forward-looking statements subject to significant risks.
Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at $14.5 billion. The company plans to fund about 73% of the deal in cash and 27% in stock, and expects the acquisition to close this year, subject to regulatory approvals and other conditions.
The transaction is designed to expand Boston Scientific’s cardiovascular portfolio and re-establish a strong neurovascular business, adding devices that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs. Penumbra expects roughly $1.4 billion of revenue in 2025, growing more than 17% over 2024. Boston Scientific anticipates the deal will slightly dilute profits in the first full year after closing, become neutral to slightly beneficial in the second year, and more beneficial thereafter.
Penumbra Inc.'s president, Shruthi Narayan, reported a routine tax‑related share withholding. On January 15, 2026, the issuer withheld 286 shares of common stock at $350.49 per share to cover tax obligations arising from the vesting of restricted stock units granted to her. Following this transaction, Narayan beneficially owns 26,317 shares of Penumbra common stock, held directly. This reflects an administrative adjustment tied to equity compensation rather than an open‑market sale.